Like Late Stage Research Unit

announced 6/1/2009 via Reuters

INC Research, Inc., will purchase Late Stage Research Unit from MDS, Inc.

See 29 Comparable Transactions
synopsis: MDS Inc has announced that it planns to narrow its contract research focus by selling its late stage operations and central laboratory divisions to Contract Research Organization INC Research, Inc.
buyer: INC Research, Inc. (SYNH:$3,472.40)
INC Research is a therapeutically focused contract research organization with an unrivaled reputation for conducting Phase I- Phase IV clinical development programs of the highest integrity. "
 seller: MDS, Inc. (MDZ:$231.00)
MDS Inc. is a global life sciences company that provides market-leading products and services that are used by its customers for the development of drugs, and the diagnosis and treatment of disease. The Company has more than 5,000 employees in 29 countries and net revenues of more than US$1.2 bil.
price ($mm)
$45
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/14/2009 via BusinessWire

NexMed, Inc., acquired Bio-Quant, Inc.

See 29 Comparable Transactions
synopsis: NexMed, Inc., a developer of products based on the NexACT® technology, announced the closing of its acquisition of Bio-Quant, Inc., a privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA.
buyer: NexMed, Inc. (NEXM:$0.00)
NexMed is an innovative drug developer that is leveraging its proprietary NexACT® drug delivery technology to produce a host of new medical treatments. NexMed’s drugs address a variety of health conditions, such as nail fungus, sexual disorders and more. "
 target: Bio-Quant, Inc.
Founded in 1999, Bio-Quant is the largest specialty CRO based in San Diego and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models specializing in oncology, inflammation, immunology, and metabolic diseases, including diabetes.
price ($mm)[EV]
$13 [$13]
rev ($mm)
$5
EBITDA ($mm)
EV / rev
2.5x
EV / EBITDA
announced 10/28/2009 via PR Newswire

Alpha Analytical, will acquire Boston Analytical

See 29 Comparable Transactions
synopsis: Alpha Analytical is announcing the completion of the acquisition of Boston Analytical, Inc. Established in 1987, Boston Analytical is a registered, cGMP compliant contract testing laboratory providing quality analytical and microbiological testing services to the pharmaceutical, biotech, device, cosmetic and nutritional product industries.
buyer: Alpha Analytical
Alpha Analytical, Inc. provides full-service environmental laboratory solutions for the most demanding industrial and commercial applications in the U.S. and abroad. Alpha Analytical is the largest environmental laboratory in New England and among the top 18 laboratories in the country. "
 target: Boston Analytical
Boston Analytical is committed to providing quality Analytical and Microbiological testing services to pharmaceutical companies worldwide in support of their Product Development, Release and Stability Testing objectives.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/12/2009 via Company Press Release

J O Hambro Capital Management Limited, acquired Celsis International

See 29 Comparable Transactions
synopsis: Chicago-based Celsis International, a leading global life sciences company, announces that it has been acquired by UK-based private equity firm J O Hambro and will de-list from the London Stock Exchange (LSE) and operate as a privately held company.
buyer: J O Hambro Capital Management Limited
J O Hambro Capital Management, the London-based boutique investment firm, offers an alternative to the large traditional fund management firms that have dominated the market for many years. "
 target: Celsis International
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries through our three divisions: Rapid Detection, Analytical Services and In Vitro Technologies.
price ($mm)[EV]
$55 [$52]*
rev ($mm)
$42
EBITDA ($mm)
$12
EV / rev
1.9x
EV / EBITDA
6.3x
closed 7/16/2009 via PR Newswire

Water Street Healthcare Partners, acquired AAIPharma Services

See 29 Comparable Transactions
synopsis: Water Street Healthcare Partners, a leading private equity firm focused exclusively on the health care industry, announced that it has acquired the Pharmaceutical Development division from AAIPharma Inc.
buyer: Water Street Healthcare Partners
Water Street Healthcare Partners is a leading private equity firm focused exclusively on health care. With more than $1 billion of capital under management, Water Street is one of the most active investors in the health care industry. "
 target parent: AAIPharma Inc.
target: AAIPharma Services
AAIPharma Services serves more than 300 large pharmaceutical and biotechnology companies. Its team of 450 scientists and professionals specialize in services that encompass the entire process of pharmaceutical drug development from discovery through commercialization.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/17/2009 via PR Newswire

ChemRar High-Tech Center, acquired Prudentas, LLC

See 29 Comparable Transactions
synopsis: ChemDiv, a global chemistry-driven contract research organization, announced that its ChemRar High Tech Center has acquired Prudentas LLC, one of the leading CRO companies conducting high quality Phase I - Phase IV studies in Eastern Europe.
buyer parent: ChemDiv, Inc.
buyer: ChemRar High-Tech Center
The ChemRar High-Tech Center is a unique pharma and biotechnology complex founded by innovative life science organizations in Russia. ChemRar's component companies are engaged in discovering, developing and commercializing novel drugs for partners in Russia and worldwide. "
 target: Prudentas, LLC
Prudentas is a Russian Clinical Contract Research Organization founded by and consisting of highly qualified clinical research professionals with extensive experience of working previously together as a team.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/17/2009 via PR Newswire

Chiltern International Inc., acquired Vigiun

See 29 Comparable Transactions
synopsis: Chiltern International Limited, a global Clinical Research Organization (CRO) providing clinical development and staffing services in Europe, the Americas and India, announced the acquisition of Vigiun, a full service Clinical Research Organization located in Sao Paulo, Brazil.
buyer: Chiltern International Inc.
Chiltern is a global CRO with experience running and staffing international Phase I to Phase IV clinical trials. Chiltern’s services include: Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. "
 target: Vigiun
Vigiun is a full service clinical research organization located in Sao Paulo, Brazil.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/29/2009 via BNC Analysis

JLL Partners, acquired Patheon, Inc.

See 29 Comparable Transactions
synopsis: JLL Partners Inc. has become the majority shareholder of Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry.
buyer: JLL Partners
Founded in 1988, JLL Partners is among the leading private equity investment firms in the country. Since inception, we have managed a series of private equity funds aggregating approximately $4 billion in committed capital. "
 target: Patheon, Inc.
Patheon Inc. is a leading provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon provides products and services to more than three hundred of the world's leading pharmaceutical and biotechnology companies.
price ($mm)[EV]
$89 [$300]*
rev ($mm)
$628
EBITDA ($mm)
$82
EV / rev
1.0x
EV / EBITDA
7.4x
closed 2/6/2009 via BusinessWire

WIL Research Laboratories, LLC, acquired Midwest BioResearch, LLC

See 29 Comparable Transactions
synopsis: WIL Research Laboratories, LLC and WIL Research Holding Company, Inc. announce the acquisition of Midwest BioResearch, LLC. Together, Midwest BioResearch and WIL Research shall integrate their service offerings through scientific collaboration, sharing of best practices and marketing.
buyer: WIL Research Laboratories, LLC
WIL Research Laboratories, LLC is a contract research organization that provides an interdisciplinary approach to non-clinical toxicology, pharmacology, metabolism and both clinical and non-clinical bioanalytical services. "
 target: Midwest BioResearch, LLC
Midwest BioResearch, LLC was founded in 2003 by scientists, directors and managers from major pharmaceutical companies to provide drug disposition and toxicology services.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 9/25/2017 via BusinessWire

Konica Minolta, Inc., will acquire Invicro, LLC

See 921 Comparable Transactions
synopsis: Konica Minolta, Inc. and Boston-based Invicro LLC announced that they have concluded an agreement whereby Konica Minolta will acquire Invicro, a leading provider of imaging services and software for research and drug development.
buyer: Konica Minolta, Inc. (TSE:4902:$9,557.68)
Konica Minolta, Inc. is a Japanese technology company headquartered in Tokyo. The company manufactures business and industrial imaging products, including copiers, laser printers, multi-functional peripherals (MFPs) and digital print systems for the production printing market. "
 target: Invicro, LLC
Invicro is a leading provider of imaging services and software for research and drug development. Headquartered in Boston, Massachusetts, Invicro LLC was founded in 2008 with the mission of improving the role and function of imaging in drug discovery and development across all therapeutic areas.
price ($mm)
rev ($mm)
$106
EBITDA ($mm)
$17
EV / rev
0.0x
EV / EBITDA
0.0x
closed 8/16/2017 via BusinessWire

Evotec BioSystems GmbH, acquired Aptuit, Inc.

See 29 Comparable Transactions
synopsis: Evotec announced that it has successfully completed the acquisition of Aptuit, a partner research organisation for integrated outsourced drug discovery and development solutions. This acquisition adds considerable business opportunities to further accelerate Evotec's long-term strategy to be the industry partner of choice for external innovation.
buyer: Evotec BioSystems GmbH (XTRA:EVT:$226.46)
Founded in Hamburg Germany, Evotec BioSystems GmbH is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. "
 target parent: Welsh, Carson, Anderson & Stowe
target: Aptuit, Inc.
Aptuit, Inc. (formerly Global Pharmaceutical Development, Inc.) is an emerging company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators.
price ($mm)
$300
rev ($mm)
$93
EBITDA ($mm)
$12
EV / rev
3.2x
EV / EBITDA
25.8x
announced 6/20/2017 via Company Press Release

Pamplona Capital Management LLP, will acquire PAREXEL International Corporation

See 29 Comparable Transactions
synopsis: Pamplona Capital Management, LLP has entered into a definitive agreement to acquire all of the outstanding shares of PAREXEL International Corporation, a leading global biopharmaceutical services provider. PAREXEL provides a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services.
buyer: Pamplona Capital Management LLP
Pamplona Capital Management is a London, New York, and Boston-based specialist investment manager established in 2005 that provides an alternative investment platform across private equity, fund of hedge funds, and single-manager hedge fund investments. "
 target: PAREXEL International Corporation (PRXL:$1,939.36)
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries.
price ($mm)[EV]
$4,508 [$4,923]
rev ($mm)
$2,097
EBITDA ($mm)
$343
EV / rev
2.4x
EV / EBITDA
14.6x
announced 5/10/2017 via BNC Analysis

inVentiv Health, Inc. will be merged with INC Research, Inc.,

See 29 Comparable Transactions
synopsis: INC Research Holdings, Inc., a leading global Phase I-IV Contract Research Organization ("CRO"), and inVentiv Health, Inc., a leading, global CRO and Contract Commercial Organization will merge. INC Research shareholders will own approximately 53 percent and inVentiv shareholders will own approximately 47 percent of the merged entity.
buyer: INC Research, Inc. (SYNH:$3,472.40)
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. "
 target parent: Thomas H. Lee Partners, L.P.
target: inVentiv Health, Inc.
inVentiv Health is a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market. Their Clinical Research Organization (CRO) and Contract Commercial Organization (CCO) offer a differentiated suite of services.
price ($mm)[EV]
$2,453 [$4,552]
rev ($mm)
$2,156
EBITDA ($mm)
$306
EV / rev
2.1x
EV / EBITDA
14.9x
closed 10/3/2016 via BusinessWire

Quintiles Transnational Corp. merged with IMS Health Incorporated,

See 29 Comparable Transactions
synopsis: Quintiles IMS Holdings, Inc. announced that it has successfully completed its merger of equals transaction between IMS Health Holdings, Inc. and Quintiles Transnational Holdings Inc. The merger creates a leading information and tech-enabled global healthcare service provider, and a full suite of end-to-end clinical and commercial offerings.
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. They connect configurable SaaS applications to complex healthcare data in the IMS One™ cloud platform. "
 target: Quintiles Transnational Corp. (Q:$4,497.17)
Quintiles is the world’s largest provider of biopharmaceutical development services and commercial outsourcing services. They help customers navigate the increasingly complex healthcare environment to improve efficiency and to deliver better healthcare outcomes.
price ($mm)
$8,750
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/6/2009 via BusinessWire

PPD, Inc., acquired Excel PharmaStudies Inc.

See 29 Comparable Transactions
synopsis: PPD, Inc. announced it has completed its acquisition of Excel PharmaStudies, Inc., one of the largest contract research organizations in China. The acquisition strengthens PPD’s full range of drug development services in the country and positions it to capitalize on the tremendous growth of the outsourcing market in Asia Pacific.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
 target: Excel PharmaStudies Inc.
Excel PharmaStudies, Inc. is a full-service provider of clinical research, registration, biometrics, and training and consultation services. Excel is the leading CRO in China and operates 22 offices worldwide, with more than 300 staff members.
price ($mm)
$16
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/17/2009 via PR Newswire

Pierrel SpA, purchased US Operations from Encorium Group Inc.

See 29 Comparable Transactions
synopsis: Encorium Group, Inc., a full service multinational clinical research organization, announced that is has completed the previously announced sale of the Company's U.S. business to Pierrel Research USA, Inc., a wholly-owned subsidiary of Pierrel SpA, an international contract research organization listed on Milano's Stock Exchange.
buyer: Pierrel SpA (PIELF:$0.00)
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use. "
 seller: Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
price ($mm)[EV]
$0.08 [$2.58]
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 4/8/2009 via PR Newswire

Next Fuel, Inc., will acquire Clinical Trials of the Americas, Inc.

See 29 Comparable Transactions
synopsis: Clinical Trials of America Inc. announced that it has entered into a binding letter of intent to sell shares equal to approximately 75% of its issued and outstanding shares to Next Fuel Inc., a developer of a proprietary "On Demand" Hydrogen Generation System.
buyer: Next Fuel, Inc.
Next Fuel Inc. is a developer of a proprietary "On Demand" Hydrogen Generation System that is used as fuel for Fuel Cells which produce electricity. "
 target: Clinical Trials of the Americas, Inc.
Clinical Trials of the Americas, Inc. provides clinical trial investigator services in dedicated sites throughout the Americas. Initially, we intend to introduce our services in Central America.
price ($mm)
$0.29*
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/2/2009 via PR Newswire

ASG, Inc., acquired Ockham Development Group, Inc.

See 29 Comparable Transactions
synopsis: ASG, Inc. a high-quality functional outsourcing and specialty staffing services group based in Cary, North Carolina - has acquired neighboring Ockham Development Group, Inc., a full-service contract research organization.
buyer: ASG, Inc.
ASG provides high-quality functional outsourcing and specialty staffing services to CROs, pharmaceutical, biotech and medical device companies that require clinical operations, GCP, GLP or GMP auditing, data management, statistical programming, biostatistics and medical writing solutions. "
 target: Ockham Development Group, Inc.
Ockham Development Group Inc. is a privately held contract research organization headquartered in Cary, North Carolina.
price ($mm)
rev ($mm)
$12
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 4/22/2009 via BusinessWire

PPD, Inc., acquired AbCRO, Inc.

See 29 Comparable Transactions
synopsis: PPD, Inc. announced that it has completed the acquisition of AbC.R.O., Inc., a Bulgarian contract research organization. The acquisition strengthens PPD’s ability to provide a broad range of clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs services to its growing client base in the Balkans.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
 target: AbCRO, Inc.
AbCRO provides a full range of Phase II-IV clinical services, including clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs.
price ($mm)
$36
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/20/2009 via PR Newswire

PharmaNet Development Group, Inc. merged with JLL Partners,

See 29 Comparable Transactions
synopsis: JLL Partners, a leading private equity investment fund, and PharmaNet Development Group, Inc., a leading provider of clinical development services, announced the successful completion of the tender offer by JLL PharmaNet Holdings, LLC.
buyer: JLL Partners
Founded in 1988, JLL Partners is among the leading private equity investment firms in the country. Since inception, we have managed a series of private equity funds aggregating approximately $4 billion in committed capital. "
 target: PharmaNet Development Group, Inc.
PharmaNet Development Group, Inc. is a leader in outsourced clinical development that offers clinical-development solutions including early and late stage consulting services, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs.
price ($mm)[EV]
$101 [$186]
rev ($mm)
$451
EBITDA ($mm)
$26
EV / rev
0.4x
EV / EBITDA
7.1x
Pages:  
announced 6/1/2009 via Reuters

INC Research, Inc., will purchase Late Stage Research Unit from MDS, Inc.

See 29 Comparable Transactions
synopsis: MDS Inc has announced that it planns to narrow its contract research focus by selling its late stage operations and central laboratory divisions to Contract Research Organization INC Research, Inc.
buyer: INC Research, Inc. (SYNH:$3,472.40)
INC Research is a therapeutically focused contract research organization with an unrivaled reputation for conducting Phase I- Phase IV clinical development programs of the highest integrity. "
 seller: MDS, Inc. (MDZ:$231.00)
MDS Inc. is a global life sciences company that provides market-leading products and services that are used by its customers for the development of drugs, and the diagnosis and treatment of disease. The Company has more than 5,000 employees in 29 countries and net revenues of more than US$1.2 bil.
price ($mm)
$45
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 5/10/2017 via BNC Analysis

inVentiv Health, Inc. will be merged with INC Research, Inc.,

See 29 Comparable Transactions
synopsis: INC Research Holdings, Inc., a leading global Phase I-IV Contract Research Organization ("CRO"), and inVentiv Health, Inc., a leading, global CRO and Contract Commercial Organization will merge. INC Research shareholders will own approximately 53 percent and inVentiv shareholders will own approximately 47 percent of the merged entity.
buyer: INC Research, Inc. (SYNH:$3,472.40)
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. "
 target parent: Thomas H. Lee Partners, L.P.
target: inVentiv Health, Inc.
inVentiv Health is a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market. Their Clinical Research Organization (CRO) and Contract Commercial Organization (CCO) offer a differentiated suite of services.
price ($mm)[EV]
$2,453 [$4,552]
rev ($mm)
$2,156
EBITDA ($mm)
$306
EV / rev
2.1x
EV / EBITDA
14.9x
announced 6/1/2009 via Reuters

INC Research, Inc., will purchase Late Stage Research Unit from MDS, Inc.

See 29 Comparable Transactions
synopsis: MDS Inc has announced that it planns to narrow its contract research focus by selling its late stage operations and central laboratory divisions to Contract Research Organization INC Research, Inc.
buyer: INC Research, Inc. (SYNH:$3,472.40)
INC Research is a therapeutically focused contract research organization with an unrivaled reputation for conducting Phase I- Phase IV clinical development programs of the highest integrity. "
 seller: MDS, Inc. (MDZ:$231.00)
MDS Inc. is a global life sciences company that provides market-leading products and services that are used by its customers for the development of drugs, and the diagnosis and treatment of disease. The Company has more than 5,000 employees in 29 countries and net revenues of more than US$1.2 bil.
price ($mm)
$45
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/1/2009 via Reuters

INC Research, Inc., will purchase Late Stage Research Unit from MDS, Inc.

See 29 Comparable Transactions
synopsis: MDS Inc has announced that it planns to narrow its contract research focus by selling its late stage operations and central laboratory divisions to Contract Research Organization INC Research, Inc.
buyer: INC Research, Inc. (SYNH:$3,472.40)
INC Research is a therapeutically focused contract research organization with an unrivaled reputation for conducting Phase I- Phase IV clinical development programs of the highest integrity. "
 seller: MDS, Inc. (MDZ:$231.00)
MDS Inc. is a global life sciences company that provides market-leading products and services that are used by its customers for the development of drugs, and the diagnosis and treatment of disease. The Company has more than 5,000 employees in 29 countries and net revenues of more than US$1.2 bil.
price ($mm)
$45
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 9/25/2017 via BusinessWire

Konica Minolta, Inc., will acquire Invicro, LLC

See 921 Comparable Transactions
synopsis: Konica Minolta, Inc. and Boston-based Invicro LLC announced that they have concluded an agreement whereby Konica Minolta will acquire Invicro, a leading provider of imaging services and software for research and drug development.
buyer: Konica Minolta, Inc. (TSE:4902:$9,557.68)
Konica Minolta, Inc. is a Japanese technology company headquartered in Tokyo. The company manufactures business and industrial imaging products, including copiers, laser printers, multi-functional peripherals (MFPs) and digital print systems for the production printing market. "
 target: Invicro, LLC
Invicro is a leading provider of imaging services and software for research and drug development. Headquartered in Boston, Massachusetts, Invicro LLC was founded in 2008 with the mission of improving the role and function of imaging in drug discovery and development across all therapeutic areas.
price ($mm)
rev ($mm)
$106
EBITDA ($mm)
$17
EV / rev
0.0x
EV / EBITDA
0.0x
closed 8/16/2017 via BusinessWire

Evotec BioSystems GmbH, acquired Aptuit, Inc.

See 29 Comparable Transactions
synopsis: Evotec announced that it has successfully completed the acquisition of Aptuit, a partner research organisation for integrated outsourced drug discovery and development solutions. This acquisition adds considerable business opportunities to further accelerate Evotec's long-term strategy to be the industry partner of choice for external innovation.
buyer: Evotec BioSystems GmbH (XTRA:EVT:$226.46)
Founded in Hamburg Germany, Evotec BioSystems GmbH is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. "
 target parent: Welsh, Carson, Anderson & Stowe
target: Aptuit, Inc.
Aptuit, Inc. (formerly Global Pharmaceutical Development, Inc.) is an emerging company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators.
price ($mm)
$300
rev ($mm)
$93
EBITDA ($mm)
$12
EV / rev
3.2x
EV / EBITDA
25.8x
announced 6/20/2017 via Company Press Release

Pamplona Capital Management LLP, will acquire PAREXEL International Corporation

See 29 Comparable Transactions
synopsis: Pamplona Capital Management, LLP has entered into a definitive agreement to acquire all of the outstanding shares of PAREXEL International Corporation, a leading global biopharmaceutical services provider. PAREXEL provides a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services.
buyer: Pamplona Capital Management LLP
Pamplona Capital Management is a London, New York, and Boston-based specialist investment manager established in 2005 that provides an alternative investment platform across private equity, fund of hedge funds, and single-manager hedge fund investments. "
 target: PAREXEL International Corporation (PRXL:$1,939.36)
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries.
price ($mm)[EV]
$4,508 [$4,923]
rev ($mm)
$2,097
EBITDA ($mm)
$343
EV / rev
2.4x
EV / EBITDA
14.6x
announced 5/10/2017 via BNC Analysis

inVentiv Health, Inc. will be merged with INC Research, Inc.,

See 29 Comparable Transactions
synopsis: INC Research Holdings, Inc., a leading global Phase I-IV Contract Research Organization ("CRO"), and inVentiv Health, Inc., a leading, global CRO and Contract Commercial Organization will merge. INC Research shareholders will own approximately 53 percent and inVentiv shareholders will own approximately 47 percent of the merged entity.
buyer: INC Research, Inc. (SYNH:$3,472.40)
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. "
 target parent: Thomas H. Lee Partners, L.P.
target: inVentiv Health, Inc.
inVentiv Health is a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market. Their Clinical Research Organization (CRO) and Contract Commercial Organization (CCO) offer a differentiated suite of services.
price ($mm)[EV]
$2,453 [$4,552]
rev ($mm)
$2,156
EBITDA ($mm)
$306
EV / rev
2.1x
EV / EBITDA
14.9x
closed 10/3/2016 via BusinessWire

Quintiles Transnational Corp. merged with IMS Health Incorporated,

See 29 Comparable Transactions
synopsis: Quintiles IMS Holdings, Inc. announced that it has successfully completed its merger of equals transaction between IMS Health Holdings, Inc. and Quintiles Transnational Holdings Inc. The merger creates a leading information and tech-enabled global healthcare service provider, and a full suite of end-to-end clinical and commercial offerings.
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. They connect configurable SaaS applications to complex healthcare data in the IMS One™ cloud platform. "
 target: Quintiles Transnational Corp. (Q:$4,497.17)
Quintiles is the world’s largest provider of biopharmaceutical development services and commercial outsourcing services. They help customers navigate the increasingly complex healthcare environment to improve efficiency and to deliver better healthcare outcomes.
price ($mm)
$8,750
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/6/2009 via BusinessWire

PPD, Inc., acquired Excel PharmaStudies Inc.

See 29 Comparable Transactions
synopsis: PPD, Inc. announced it has completed its acquisition of Excel PharmaStudies, Inc., one of the largest contract research organizations in China. The acquisition strengthens PPD’s full range of drug development services in the country and positions it to capitalize on the tremendous growth of the outsourcing market in Asia Pacific.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
 target: Excel PharmaStudies Inc.
Excel PharmaStudies, Inc. is a full-service provider of clinical research, registration, biometrics, and training and consultation services. Excel is the leading CRO in China and operates 22 offices worldwide, with more than 300 staff members.
price ($mm)
$16
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/17/2009 via PR Newswire

Pierrel SpA, purchased US Operations from Encorium Group Inc.

See 29 Comparable Transactions
synopsis: Encorium Group, Inc., a full service multinational clinical research organization, announced that is has completed the previously announced sale of the Company's U.S. business to Pierrel Research USA, Inc., a wholly-owned subsidiary of Pierrel SpA, an international contract research organization listed on Milano's Stock Exchange.
buyer: Pierrel SpA (PIELF:$0.00)
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use. "
 seller: Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
price ($mm)[EV]
$0.08 [$2.58]
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 4/8/2009 via PR Newswire

Next Fuel, Inc., will acquire Clinical Trials of the Americas, Inc.

See 29 Comparable Transactions
synopsis: Clinical Trials of America Inc. announced that it has entered into a binding letter of intent to sell shares equal to approximately 75% of its issued and outstanding shares to Next Fuel Inc., a developer of a proprietary "On Demand" Hydrogen Generation System.
buyer: Next Fuel, Inc.
Next Fuel Inc. is a developer of a proprietary "On Demand" Hydrogen Generation System that is used as fuel for Fuel Cells which produce electricity. "
 target: Clinical Trials of the Americas, Inc.
Clinical Trials of the Americas, Inc. provides clinical trial investigator services in dedicated sites throughout the Americas. Initially, we intend to introduce our services in Central America.
price ($mm)
$0.29*
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/2/2009 via PR Newswire

ASG, Inc., acquired Ockham Development Group, Inc.

See 29 Comparable Transactions
synopsis: ASG, Inc. a high-quality functional outsourcing and specialty staffing services group based in Cary, North Carolina - has acquired neighboring Ockham Development Group, Inc., a full-service contract research organization.
buyer: ASG, Inc.
ASG provides high-quality functional outsourcing and specialty staffing services to CROs, pharmaceutical, biotech and medical device companies that require clinical operations, GCP, GLP or GMP auditing, data management, statistical programming, biostatistics and medical writing solutions. "
 target: Ockham Development Group, Inc.
Ockham Development Group Inc. is a privately held contract research organization headquartered in Cary, North Carolina.
price ($mm)
rev ($mm)
$12
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 4/22/2009 via BusinessWire

PPD, Inc., acquired AbCRO, Inc.

See 29 Comparable Transactions
synopsis: PPD, Inc. announced that it has completed the acquisition of AbC.R.O., Inc., a Bulgarian contract research organization. The acquisition strengthens PPD’s ability to provide a broad range of clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs services to its growing client base in the Balkans.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
 target: AbCRO, Inc.
AbCRO provides a full range of Phase II-IV clinical services, including clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs.
price ($mm)
$36
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/20/2009 via PR Newswire

PharmaNet Development Group, Inc. merged with JLL Partners,

See 29 Comparable Transactions
synopsis: JLL Partners, a leading private equity investment fund, and PharmaNet Development Group, Inc., a leading provider of clinical development services, announced the successful completion of the tender offer by JLL PharmaNet Holdings, LLC.
buyer: JLL Partners
Founded in 1988, JLL Partners is among the leading private equity investment firms in the country. Since inception, we have managed a series of private equity funds aggregating approximately $4 billion in committed capital. "
 target: PharmaNet Development Group, Inc.
PharmaNet Development Group, Inc. is a leader in outsourced clinical development that offers clinical-development solutions including early and late stage consulting services, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs.
price ($mm)[EV]
$101 [$186]
rev ($mm)
$451
EBITDA ($mm)
$26
EV / rev
0.4x
EV / EBITDA
7.1x
closed 1/27/2009 via BusinessWire

Altarum Institute, acquired KAI Research, Inc.

See 29 Comparable Transactions
synopsis: Altarum Institute, a non-profit health systems research and consulting organization, has purchased Rockville, Maryland-based KAI Research, Inc. (KAI). KAI provides innovative, cost-effective and practical support to the pharmaceutical and biotech industry, academic institutions and the National Institutes of Health.
buyer: Altarum Institute
Altarum Institute is a nonprofit health systems research and consulting organization serving government and private-sector clients. "
 target: KAI Research, Inc.
KAI Research provides innovative, cost-effective and practical support to the pharmaceutical and biotech industries. KAI currently supports pharmaco-vigilance activities for over 90 marketed drugs and is providing safety surveillance for dozens of ongoing clinical trials.
price ($mm)
$7.55
rev ($mm)
$10
EBITDA ($mm)
EV / rev
0.8x
EV / EBITDA
closed 3/13/2009 via BNC Analysis

Premier Research Group, acquired Pivotal Research Centers, LLC

See 29 Comparable Transactions
synopsis: PHC, Inc. d/b/a Pioneer Behavioral Health, a leading provider of inpatient and outpatient behavioral health services, announced Premier Research Arizona, LLC, a unit of Premier Research Group PLC, has signed a purchase agreement to acquire the assets of PHC's Pivotal Research Centers.
buyer: Premier Research Group
Premier Research is a leading solutions-driven CRO committed to therapeutic focus and operational expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. "
 target parent: Pioneer Behavioral Health
target: Pivotal Research Centers, LLC
Pivotal Research Centers, LLC provides clinical drug testing. It performs all phases of clinical research for Phase I to Phase IV drugs under development through two research sites. Pivotal was founded by Louis C. Kirby in 1993 and is based in Phoenix, Arizona.
price ($mm)
$3.00
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/30/2007 via Company Press Release

Chiltern International Inc., acquired Clinical Trial Management Services, Inc.

See 29 Comparable Transactions
synopsis: Chiltern, a leading global clinical research organization (CRO), announced the acquisition of Clinical Trial Management Services, Inc. (CTMS) a Bristol, Tennessee based CRO offering high quality services throughout the United States.
buyer: Chiltern International Inc.
Chiltern is a global CRO with experience running and staffing international Phase I to Phase IV clinical trials. Chiltern’s services include: Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. "
 target: Clinical Trial Management Services, Inc.
Clinical Trial Management Services, Inc. provides clinical research services such as clinical trial management and monitoring services, such as project management, investigative site management and monitoring services.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/14/2009 via BusinessWire

NexMed, Inc., acquired Bio-Quant, Inc.

See 29 Comparable Transactions
synopsis: NexMed, Inc., a developer of products based on the NexACT® technology, announced the closing of its acquisition of Bio-Quant, Inc., a privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA.
buyer: NexMed, Inc. (NEXM:$0.00)
NexMed is an innovative drug developer that is leveraging its proprietary NexACT® drug delivery technology to produce a host of new medical treatments. NexMed’s drugs address a variety of health conditions, such as nail fungus, sexual disorders and more. "
 target: Bio-Quant, Inc.
Founded in 1999, Bio-Quant is the largest specialty CRO based in San Diego and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models specializing in oncology, inflammation, immunology, and metabolic diseases, including diabetes.
price ($mm)[EV]
$13 [$13]
rev ($mm)
$5
EBITDA ($mm)
EV / rev
2.5x
EV / EBITDA
announced 10/28/2009 via PR Newswire

Alpha Analytical, will acquire Boston Analytical

See 29 Comparable Transactions
synopsis: Alpha Analytical is announcing the completion of the acquisition of Boston Analytical, Inc. Established in 1987, Boston Analytical is a registered, cGMP compliant contract testing laboratory providing quality analytical and microbiological testing services to the pharmaceutical, biotech, device, cosmetic and nutritional product industries.
buyer: Alpha Analytical
Alpha Analytical, Inc. provides full-service environmental laboratory solutions for the most demanding industrial and commercial applications in the U.S. and abroad. Alpha Analytical is the largest environmental laboratory in New England and among the top 18 laboratories in the country. "
 target: Boston Analytical
Boston Analytical is committed to providing quality Analytical and Microbiological testing services to pharmaceutical companies worldwide in support of their Product Development, Release and Stability Testing objectives.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/12/2009 via Company Press Release

J O Hambro Capital Management Limited, acquired Celsis International

See 29 Comparable Transactions
synopsis: Chicago-based Celsis International, a leading global life sciences company, announces that it has been acquired by UK-based private equity firm J O Hambro and will de-list from the London Stock Exchange (LSE) and operate as a privately held company.
buyer: J O Hambro Capital Management Limited
J O Hambro Capital Management, the London-based boutique investment firm, offers an alternative to the large traditional fund management firms that have dominated the market for many years. "
 target: Celsis International
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries through our three divisions: Rapid Detection, Analytical Services and In Vitro Technologies.
price ($mm)[EV]
$55 [$52]*
rev ($mm)
$42
EBITDA ($mm)
$12
EV / rev
1.9x
EV / EBITDA
6.3x
closed 7/16/2009 via PR Newswire

Water Street Healthcare Partners, acquired AAIPharma Services

See 29 Comparable Transactions
synopsis: Water Street Healthcare Partners, a leading private equity firm focused exclusively on the health care industry, announced that it has acquired the Pharmaceutical Development division from AAIPharma Inc.
buyer: Water Street Healthcare Partners
Water Street Healthcare Partners is a leading private equity firm focused exclusively on health care. With more than $1 billion of capital under management, Water Street is one of the most active investors in the health care industry. "
 target parent: AAIPharma Inc.
target: AAIPharma Services
AAIPharma Services serves more than 300 large pharmaceutical and biotechnology companies. Its team of 450 scientists and professionals specialize in services that encompass the entire process of pharmaceutical drug development from discovery through commercialization.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/17/2009 via PR Newswire

ChemRar High-Tech Center, acquired Prudentas, LLC

See 29 Comparable Transactions
synopsis: ChemDiv, a global chemistry-driven contract research organization, announced that its ChemRar High Tech Center has acquired Prudentas LLC, one of the leading CRO companies conducting high quality Phase I - Phase IV studies in Eastern Europe.
buyer parent: ChemDiv, Inc.
buyer: ChemRar High-Tech Center
The ChemRar High-Tech Center is a unique pharma and biotechnology complex founded by innovative life science organizations in Russia. ChemRar's component companies are engaged in discovering, developing and commercializing novel drugs for partners in Russia and worldwide. "
 target: Prudentas, LLC
Prudentas is a Russian Clinical Contract Research Organization founded by and consisting of highly qualified clinical research professionals with extensive experience of working previously together as a team.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
Pages:  

Like Late Stage Research Unit


read more

MDS, Inc.

Bio-Quant, Inc.

Boston Analytical

Celsis International

AAIPharma Services

Prudentas, LLC

Vigiun

Patheon, Inc.

Midwest BioResearch, LLC

Invicro, LLC

Aptuit, Inc.

PAREXEL International Corporation

inVentiv Health, Inc.

Quintiles Transnational Corp.

Excel PharmaStudies Inc.

Encorium Group Inc.

Clinical Trials of the Americas, Inc.

Ockham Development Group, Inc.

AbCRO, Inc.

PharmaNet Development Group, Inc.

Pages:  
read more

MDS, Inc.

read more

inVentiv Health, Inc.

MDS, Inc.

read more

MDS, Inc.

Invicro, LLC

Aptuit, Inc.

PAREXEL International Corporation

inVentiv Health, Inc.

Quintiles Transnational Corp.

Excel PharmaStudies Inc.

Encorium Group Inc.

Clinical Trials of the Americas, Inc.

Ockham Development Group, Inc.

AbCRO, Inc.

PharmaNet Development Group, Inc.

KAI Research, Inc.

Pivotal Research Centers, LLC

Clinical Trial Management Services, Inc.

Bio-Quant, Inc.

Boston Analytical

Celsis International

AAIPharma Services

Prudentas, LLC

Pages:  
Geography
Matching Companies
Ticker: SYNH
 
 
 
 
 
 
 
 
INC Research, Inc.
INC Research, Inc.
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries.
year
2018
rev ($mm)
$3,472.40
EBITDA ($mm)
$441.82
EBIT ($mm)
$157.52
Net Income ($mm)
Employees
21000
  • drill down
  • watch
Ticker: ICLR
 
 
 
 
 
 
 
 
ICON Plc
ICON Plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development.
year
2015
rev ($mm)
$1,541.91
EBITDA ($mm)
$289.74
EBIT ($mm)
$234.82
Net Income ($mm)
$192.14
Employees
11200
  • drill down
  • watch
Ticker:
 
 
 
 
 
 
 
 
CMIC Co., Ltd.
CMIC is a leading full-service CRO in Japan offering a wide range of services in clinical trials in Asia to both multi-national and Japanese pharma companies.
year
2019
rev ($mm)
$664.65
EBITDA ($mm)
$76.21
EBIT ($mm)
$43.15
Net Income ($mm)
$23.12
Employees
4962
  • drill down
  • watch
Ticker: PIELF
 
 
 
 
 
 
 
 
Pierrel SpA
Pierrel SpA
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use.
year
2008
rev ($mm)
$64.38
EBITDA ($mm)
($4.23)
EBIT ($mm)
($8.92)
Net Income ($mm)
Employees
504
  • drill down
  • watch
Ticker: ENCO
 
 
 
 
 
 
 
 
Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
year
2008
rev ($mm)
$35.91
EBITDA ($mm)
($5.19)
EBIT ($mm)
($6.89)
Net Income ($mm)
Employees
226
  • drill down
  • watch
Ticker: CRL
 
 
 
 
 
 
 
 
Charles River Laboratories International Inc.
Charles River Laboratories International Inc.
Charles River has been helping our global partners accelerate drug discovery and development by providing them with tailored research models and preclinical, clinical, support services.
year
2009
rev ($mm)
$1,202.55
EBITDA ($mm)
$282.48
EBIT ($mm)
$188.93
Net Income ($mm)
$114.44
Employees
8000
  • drill down
  • watch
Ticker: ENXTPA:ERF
 
 
 
 
 
 
 
 
Eurofins Group
Eurofins Group
Based in Luxembourg, Eurofins is a leading international group of laboratories providing a unique range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments.
year
2017
rev ($mm)
$3,467.64
EBITDA ($mm)
$637.81
EBIT ($mm)
$406.82
Net Income ($mm)
$252.97
Employees
34651
  • drill down
  • watch
Ticker: LH
 
 
 
 
 
 
 
 
LabCorp
LabCorp provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories. LabCorp processes tests on approximately 470,000 specimens each day, applying advances in medicine and science to laboratory testing.
year
2009
rev ($mm)
$4,694.70
EBITDA ($mm)
$1,142.70
EBIT ($mm)
$949.40
Net Income ($mm)
$543.30
Employees
28000
  • drill down
  • watch
Ticker: SYNH
 
 
 
 
 
 
 
 
INC Research, Inc.
INC Research, Inc.
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries.
year
2018
rev ($mm)
$3,472.40
EBITDA ($mm)
$441.82
EBIT ($mm)
$157.52
Net Income ($mm)
Employees
21000
  • drill down
  • watch
Ticker: ICLR
 
 
 
 
 
 
 
 
ICON Plc
ICON Plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development.
year
2015
rev ($mm)
$1,541.91
EBITDA ($mm)
$289.74
EBIT ($mm)
$234.82
Net Income ($mm)
$192.14
Employees
11200
  • drill down
  • watch
Ticker:
 
 
 
 
 
 
 
 
CMIC Co., Ltd.
CMIC is a leading full-service CRO in Japan offering a wide range of services in clinical trials in Asia to both multi-national and Japanese pharma companies.
year
2019
rev ($mm)
$664.65
EBITDA ($mm)
$76.21
EBIT ($mm)
$43.15
Net Income ($mm)
$23.12
Employees
4962
  • drill down
  • watch
Ticker: PIELF
 
 
 
 
 
 
 
 
Pierrel SpA
Pierrel SpA
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use.
year
2008
rev ($mm)
$64.38
EBITDA ($mm)
($4.23)
EBIT ($mm)
($8.92)
Net Income ($mm)
Employees
504
  • drill down
  • watch
Ticker: ENCO
 
 
 
 
 
 
 
 
Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
year
2008
rev ($mm)
$35.91
EBITDA ($mm)
($5.19)
EBIT ($mm)
($6.89)
Net Income ($mm)
Employees
226
  • drill down
  • watch
Ticker: ENXTPA:ERF
 
 
 
 
 
 
 
 
Eurofins Group
Eurofins Group
Based in Luxembourg, Eurofins is a leading international group of laboratories providing a unique range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments.
year
2017
rev ($mm)
$3,467.64
EBITDA ($mm)
$637.81
EBIT ($mm)
$406.82
Net Income ($mm)
$252.97
Employees
34651
  • drill down
  • watch
Ticker: CRL
 
 
 
 
 
 
 
 
Charles River Laboratories International Inc.
Charles River Laboratories International Inc.
Charles River has been helping our global partners accelerate drug discovery and development by providing them with tailored research models and preclinical, clinical, support services.
year
2009
rev ($mm)
$1,202.55
EBITDA ($mm)
$282.48
EBIT ($mm)
$188.93
Net Income ($mm)
$114.44
Employees
8000
  • drill down
  • watch
Ticker: LH
 
 
 
 
 
 
 
 
LabCorp
LabCorp provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories. LabCorp processes tests on approximately 470,000 specimens each day, applying advances in medicine and science to laboratory testing.
year
2009
rev ($mm)
$4,694.70
EBITDA ($mm)
$1,142.70
EBIT ($mm)
$949.40
Net Income ($mm)
$543.30
Employees
28000
  • drill down
  • watch